Maximus, Inc. $MMS Shares Purchased by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. grew its position in shares of Maximus, Inc. (NYSE:MMS) by 51.3% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 65,800 shares of the health services provider’s stock after acquiring an additional 22,300 shares during the quarter. Hillsdale Investment Management Inc.’s holdings in Maximus were worth $4,619,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Savant Capital LLC raised its holdings in shares of Maximus by 84.1% during the 2nd quarter. Savant Capital LLC now owns 10,055 shares of the health services provider’s stock valued at $706,000 after buying an additional 4,594 shares during the period. Bank of New York Mellon Corp grew its position in Maximus by 1.6% in the second quarter. Bank of New York Mellon Corp now owns 549,369 shares of the health services provider’s stock valued at $38,566,000 after acquiring an additional 8,434 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Maximus during the first quarter valued at approximately $2,115,000. Nordea Investment Management AB lifted its position in shares of Maximus by 0.6% during the second quarter. Nordea Investment Management AB now owns 64,829 shares of the health services provider’s stock worth $4,542,000 after purchasing an additional 382 shares in the last quarter. Finally, AlphaQuest LLC boosted its stake in shares of Maximus by 142.0% in the second quarter. AlphaQuest LLC now owns 8,663 shares of the health services provider’s stock valued at $608,000 after purchasing an additional 5,083 shares during the period. 97.21% of the stock is owned by institutional investors and hedge funds.

Maximus Trading Up 3.7%

Shares of NYSE MMS opened at $85.06 on Friday. The company has a quick ratio of 2.27, a current ratio of 2.27 and a debt-to-equity ratio of 0.91. The stock’s 50 day moving average price is $85.86 and its two-hundred day moving average price is $79.48. Maximus, Inc. has a 52-week low of $63.77 and a 52-week high of $92.50. The stock has a market capitalization of $4.79 billion, a P/E ratio of 15.66 and a beta of 0.57.

Maximus (NYSE:MMS) last issued its earnings results on Thursday, November 20th. The health services provider reported $1.62 EPS for the quarter, missing the consensus estimate of $1.63 by ($0.01). The firm had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.34 billion. Maximus had a return on equity of 24.44% and a net margin of 5.83%.Maximus’s revenue was up .2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $1.46 EPS. Maximus has set its FY 2026 guidance at 7.950-8.250 EPS. On average, analysts anticipate that Maximus, Inc. will post 6.15 earnings per share for the current fiscal year.

Maximus Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be paid a dividend of $0.30 per share. The ex-dividend date is Friday, November 14th. This represents a $1.20 annualized dividend and a yield of 1.4%. Maximus’s payout ratio is presently 22.10%.

Insider Buying and Selling at Maximus

In other Maximus news, insider Michelle F. Link sold 1,610 shares of the stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $90.86, for a total transaction of $146,284.60. Following the sale, the insider directly owned 13,508 shares of the company’s stock, valued at approximately $1,227,336.88. This represents a 10.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 1.60% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MMS. Zacks Research lowered shares of Maximus from a “strong-buy” rating to a “hold” rating in a report on Monday, October 27th. Weiss Ratings cut Maximus from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Thursday. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $90.00.

About Maximus

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.